NEW YORK, April 8, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B (HBV) and hepatitis D (HDV) patients, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted six abstracts for presentation at the EASL 2015 annual meeting to be held April 22-26, 2015 in Vienna, Austria.
Four presentations, one oral and three poster, disclose new clinical and mechanistic data on the activity of nucleic acid polymers (NAPs) against chronic hepatitis B infection:
Two late breaking presentations, one oral and one poster, disclose new clinical and mechanistic data on the activity of NAPs against chronic hepatitis B / hepatitis D co-infection:
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For the 2015 EASL Meeting: https://ilc-congress.eu/.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com or follow us on Twitter @replicorinc.